Valuation: Elutia Inc.

Market Cap 41.48M 36.32M 33.53M 31.31M 58.93M 3.92B 60.28M 403M 156M 1.93B 156M 152M 6.72B P/E 2026 *
-1.59x
P/E 2027 * -1.84x
Enterprise Value 41.48M 36.32M 33.53M 31.31M 58.93M 3.92B 60.28M 403M 156M 1.93B 156M 152M 6.72B EV / Sales 2026 *
3.46x
EV / Sales 2027 * 3.17x
Free-Float
85.23%
Yield 2026 *
-
Yield 2027 * -
1 day-4.25%
1 week-4.35%
Current month-17.54%
1 month-17.54%
3 months-10.61%
6 months+75.89%
Current year+38.08%
1 week 0.93
Extreme 0.93
1.04
1 month 0.93
Extreme 0.93
1.17
Current year 0.6
Extreme 0.6019
1.38
1 year 0.5
Extreme 0.5
2.64
3 years 0.5
Extreme 0.5
5.24
5 years 0.5
Extreme 0.5
9.99
10 years 0.5
Extreme 0.5
18.2
Manager TitleAgeSince
Chief Operating Officer 52 -
Chief Executive Officer 54 2022-06-20
Director of Finance/CFO 58 2020-09-27
Director TitleAgeSince
Chairman 65 2015-10-31
Director/Board Member 54 2015-10-31
Director/Board Member 70 2020-08-31
Date Insider Type Main position Quantity % Market Cap.
06-20Fiscal year

Founder

53,010 0.1199%
06-10Free

Director

106,393 0.2407%
06-10Free

Director

106,393 0.2407%
Change 5-day change 1-year change 3-year change Capi.($)
-4.25%-4.35%-54.45%-58.59% 44.16M
-0.17%+3.15%+21.27%-10.81% 64.39B
+1.93%+6.42%+54.82%+229.54% 56.12B
+7.82%+44.80%+44.80%+44.80% 40.54B
+0.10%+2.96%-51.83%-58.41% 37.98B
+0.28%+8.47%+71.82%-23.22% 31.89B
+3.61%+17.45%+156.63%-42.92% 26.69B
+0.80%+10.61%+67.71%+85.38% 22.73B
+6.52%+6.24%+3.49%+176.51% 16.66B
-0.77%+4.00%+62.54%+123.05% 16.6B
Average +1.57%+6.55%+37.68%+46.53% 31.36B
Weighted average by Cap. +2.02%+7.30%+42.71%+53.62%

Financials

2026 *2027 *
Net sales 12M 10.51M 9.7M 9.06M 17.05M 1.13B 17.44M 117M 45.06M 560M 45.06M 44.08M 1.94B 13.1M 11.47M 10.59M 9.89M 18.61M 1.24B 19.04M 127M 49.19M 611M 49.2M 48.12M 2.12B
Net income -25.9M -22.68M -20.94M -19.55M -36.8M -2.45B -37.64M -252M -97.26M -1.21B -97.26M -95.13M -4.19B -22.4M -19.61M -18.11M -16.91M -31.83M -2.12B -32.55M -218M -84.12M -1.04B -84.12M -82.28M -3.63B
Net Debt - -
Logo Elutia Inc.
Elutia Inc. is a commercial-stage company, which has developed a portfolio of products using both human and porcine tissue. Its portfolio of products spans the Women’s Health and Cardiovascular markets. In Women’s Health, it offers SimpliDerm, a novel biological matrix that leverages the inherent science of natural healing processes. SimpliDerm's design uses human-based hydrated acellular dermal matrix (ADM), which mitigates inflammation and enhances tissue incorporation. In Cardiovascular, it sells its specialized porcine small intestine submucosa for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population. It is focused on advancing NXT-41x, a biomatrix that directly addresses the root causes of reconstruction infections following mastectomy. NXT-41x combines biologics and extended antibiotic release to provide protection while supporting tissue regeneration.
Employees
26
Date Price Change Volume
26-06-29 US$0.9565 -4.25% 140,583
26-06-26 US$0.9990 +5.37% 91,816
26-06-25 US$0.9481 -3.36% 66,927
26-06-24 US$0.9811 -4.75% 95,591
26-06-23 US$1.030 +3.00% 76,451
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.9382USD
Average target price
5.000USD
Spread / Average Target
+432.94%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ELUT Stock